Drug Profile
L 870810
Alternative Names: L 000870810; L-870810Latest Information Update: 03 Oct 2007
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antiretrovirals; Naphthyridines
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Jul 2006 Discontinued - Phase-I for HIV infections treatment in USA (PO)
- 11 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the adverse events and Viral Infections therapeutic trials sections
- 08 Sep 2004 Data presented at the 228th ACS National Meeting (228-ACS-2004) have been added to the Viral Infections antimicrobial activity section